Table 1 |
||||
|
Comparison of the success of antibodies to Ro52, Ro60, or La at inducing heart block in experimental models |
||||
|
Inducing factor |
Species (strain) |
Proportion of AVB, percentagea |
AVB II/III, percentagea |
Reference |
|
|
||||
|
Antibody transfer during gestation (specificity/antigen) |
||||
|
Ro52 and Ro60 |
Mouse (BALB/c) |
47-100 |
0 |
Mazel, et al. [58] (1998) |
|
Ro52/p200 (aa 200-239) |
Rat (DA) |
100 |
0 |
Ambrosi, et al. [59] (2012) |
|
Ro52/N- or C-terminal |
Rat (DA) |
0 |
0 |
|
|
Immunization before gestation (specificity/antigen) |
||||
|
Ro52 |
Mouse (BALB/c) |
25 |
10 |
Boutjdir, et al. [50] (1997) |
|
Ro52 |
Mouse (BALB/c) |
9 |
3.6 |
Miranda-Carus, et al. [53] (1998) |
|
Ro52 |
Rabbit (New Zealand) |
9 |
0.7 (20% pups born dead) |
Xiao, et al. [56] (2001) |
|
Ro52 |
Rat (DA) |
45 |
0 |
Strandberg, et al. [55] (2010) |
|
Rat (LEW) |
10 |
0 |
||
|
Rat (PVG) |
44 |
0 |
||
|
Ro52β |
Mouse (BALB/c) |
12 |
6 |
Miranda-Carus, et al. [53] (1998) |
|
Ro52 (mouse) |
Mouse (BALB/c) |
9 |
0 |
|
|
Ro52 (aa 365-382) |
Mouse (BALB/c) |
0 |
0 |
Eftekhari, et al. [64] (2001) |
|
Ro52 (aa 366-379) |
Mouse (BALB/c) |
0 |
0 |
|
|
Ro52/p200 (aa 200-239) |
Rat (DA) |
19 |
0 |
Salomonsson, et al. [45] (2005) |
|
Ro60 |
Mouse (BALB/c) |
19 |
0 |
Miranda-Carus, et al. [53] (1998) |
|
Ro60b |
Mouse (C3H/HEJ) |
14 |
0 |
Suzuki, et al. [54] (2005) |
|
La |
Mouse (BALB/c) |
7 |
0 |
Miranda-Carus, et al. [53] (1998) |
|
Lab |
Mouse (C3H/HEJ) |
7 |
0 |
Suzuki, et al. [54] (2005) |
|
Ro52, Ro60, and La |
Mouse (FBV Cav1.2 non-transgenic littermates) |
28 |
5.5 |
Karnabi, et al. [68] (2011) |
|
Mouse (FBV Cav1.2 transgenic) |
9 |
1.1 |
||
|
Mouse (C57BL/6 Cav1.3+/+) |
18 |
3 |
||
|
Mouse (C57BL/6 Cav1.3-/-) |
100 |
44 |
||
|
|
||||
|
aAtrioventricular block (AVB) determined by neonatal electrocardiogram recording. bThe authors report the presence of anti-Ro or anti-La antibodies in the serum of mice immunized with La or Ro60, respectively. aa, amino acids; DA, Dark Agouti. |
||||
|
Ambrosi and Wahren-Herlenius Arthritis Research & Therapy 2012 14:208 doi:10.1186/ar3787 |
||||